Trial Profile
A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs VGX 3100 (Primary) ; Imiquimod
- Indications Human papillomavirus infections; Vulvar intraepithelial neoplasia
- Focus Proof of concept; Therapeutic Use
- Sponsors Inovio Pharmaceuticals
- 15 Nov 2021 According to an Inovio Pharmaceuticals media release, results from this trial will be presented at the 34th International Papillomavirus Conference (IPVC) 2021.
- 01 Sep 2021 Status changed from active, no longer recruiting to completed.
- 06 Jan 2021 Results presented in an Inovio AS Media Release.